ARMS Primers for KRAS Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting KRAS mutations, particularly in cancer diagnosis, face challenges due to non-specific hybridization and low-abundance mutation detection, leading to inaccurate results and inability to detect mutations below 20% abundance.
Innovation Solution
The use of ARMS primers with 3' target-specific sequences and 5' non-target specific tags of varying lengths, combined with optimized thermal cycling conditions, allows for specific and sensitive detection of KRAS mutations, including those present in low percentages, by enhancing the specificity and reducing non-specific binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional hybridization methods are used to detect KRAS mutations, then the detection process is simple, but the specificity is poor due to non-specific hybridization between amplification products and probes
Solution Approach 1:
The detection method is divided into two independent stages: (1) ARMS amplification stage that generates mutation-specific products with unique 5' tags, and (2) detection stage that uses probes complementary to these tags. This segmentation allows each stage to be optimized independently, achieving high specificity without excessive complexity
Solution Approach 2:
The 5' tag sequence serves as an intermediary element that links the mutation-specific amplification product to the detection probe. The tag is not complementary to the target mutation sequence but provides a unique identifier that enables specific probe binding, thus mediating between the amplification and detection steps
2Measurement precision
If standard PCR amplification is used, then the amplification efficiency is high, but the ability to detect low-abundance mutations (below 20%) is insufficient
Solution Approach 1:
The ARMS primer design incorporates local quality differences through the 5' tag sequence that is unique to each mutation type. This local differentiation allows the detection system to distinguish and quantify low-abundance mutations even when they constitute less than 20% of the total DNA, achieving sensitivity below the conventional threshold
Solution Approach 2:
The method performs preliminary enrichment of mutation-specific DNA sequences through ARMS amplification before detection. By pre-amplifying only the mutation-containing sequences using mutation-specific primers, the method concentrates low-abundance mutations to detectable levels while maintaining the quantitative relationship between mutant and wild-type alleles
3Adaptability or versatility
If multiple KRAS mutations are detected simultaneously, then the diagnostic information is comprehensive, but the non-specific binding between amplification products and probes increases
Solution Approach 1:
Each mutation type is assigned a unique 5' tag sequence, creating distinct detection channels. This segmentation of the detection space allows multiple mutations to be detected simultaneously without cross-reactivity, as each probe only binds to its complementary tag sequence
Solution Approach 2:
The use of asymmetric 5' tag sequences (non-palindromic, unique to each mutation) ensures that probes designed for one mutation will not bind to amplification products of other mutations. This asymmetry in sequence design prevents non-specific binding while enabling comprehensive multiplex detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate detection of KRAS mutations at 1% or lower in a wild-type background, improving diagnostic sensitivity and specificity, and is applicable for cancer diagnosis and predicting response to anti-EGFR therapies.
Implementation Method 1
ARMS primers with 3' target-specific sequences and 5' non-target specific tags
Implementation Method 2
optimized thermal cycling conditions
Data Source
AI summary
The present invention is based on a detection method of the 9 KRAS mutations Gly12Ser, Gly12Arg, Gly12Cys, Gly12Asp, Gly12Ala, Gly12Val, Gly13Asp, Gln61His and Gln61Leu, in a sample susceptible of containing one or more of such mutations, based on amplification of the sample with the primers of the present invention. Further, the present invention relates to (i) a kit which comprises, amongst its components, reagents for ARMS amplification including one or more of the primers of the present invention; (ii) the primers themselves; and (iii) use of the method, kit and primers of above, for the diagnosis/prognosis of a pathological condition in a patient, particularly, of cancer.